COVID Antibody Treatments Show Promise For Preventing Severe Disease-Scientific American

Two clinical trials suggest that specific antibody treatments can prevent deaths and hospitalizations among people with mild or moderate COVID-19—particularly those who are at high risk of developing severe disease. One study found that an antibody against the coronavirus developed by Vir Biotechnology in San Francisco, California, and GSK, headquartered in London, reduced the chances of hospitalization or death among participants by 85%. In another trial, a cocktail of two antibodies—bamlanivimab and etesevimab, both made by Eli Lilly of Indianapolis, Indiana—cut the risk of hospitalization and death by 87%. Scientific American, 03/17/2021

•   Print
•   Email
•   Share
•   Tweet